Sotera Health (NASDAQ:SHC) Stock Rating Upgraded by Wall Street Zen

Sotera Health (NASDAQ:SHC - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

A number of other equities research analysts have also commented on the company. Barclays dropped their price target on Sotera Health from $15.00 to $13.00 and set an "overweight" rating on the stock in a research report on Tuesday. Piper Sandler dropped their target price on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group upgraded shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their price target for the company from $14.00 to $17.00 in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Sotera Health Stock Performance

Shares of NASDAQ:SHC opened at $11.32 on Friday. The firm's 50 day simple moving average is $12.00 and its 200 day simple moving average is $12.38. Sotera Health has a fifty-two week low of $9.53 and a fifty-two week high of $17.08. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of 141.52 and a beta of 1.87. The company has a debt-to-equity ratio of 5.55, a current ratio of 2.46 and a quick ratio of 2.19.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The company had revenue of $254.52 million for the quarter, compared to analysts' expectations of $245.56 million. During the same period last year, the firm posted $0.13 earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Institutional Investors Weigh In On Sotera Health

Institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Sotera Health in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd grew its position in Sotera Health by 3,690.1% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company's stock valued at $31,000 after purchasing an additional 2,620 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Sotera Health in the 1st quarter valued at $67,000. Farther Finance Advisors LLC lifted its position in Sotera Health by 4,881.9% during the 1st quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company's stock worth $70,000 after buying an additional 6,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Sotera Health by 37.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after buying an additional 1,640 shares in the last quarter. Institutional investors own 91.03% of the company's stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.